Loading organizations...

§ Private Profile · 8170 Jackson Road Suite A Ann Arbor, MI 48103 United States
Strata Oncology is a technology company.
Strata Oncology provides precision oncology solutions through advanced biomarker testing. The company develops proprietary diagnostic tools, including an Antibody-drug Conjugate Treatment Response Score and an Immunotherapy Response Score. These algorithmic biomarkers analyze tumor biology, predicting patient response to specific therapies like ADCs and anti-PD-1/PD-L1 immunotherapies, guiding oncologists toward optimal strategies.
Founded in 2015 by Dan Rhodes, PhD, Scott Tomlins, MD, PhD, and Keith Flaherty, MD, Strata Oncology addressed a critical need for precise patient-treatment matching. Rhodes, a cancer genomics entrepreneur, and his co-founders recognized advanced molecular insights could transform therapeutic decision-making.
Strata Oncology’s services assist oncologists and healthcare systems in selecting targeted cancer therapies. The company’s vision ensures every patient receives their most effective treatment. Its mission accelerates precision medicine by integrating deep tumor biology understanding into routine clinical practice, transforming cancer therapy.
Strata Oncology has raised $128.0M across 3 funding rounds.
Strata Oncology has raised $128.0M in total across 3 funding rounds.
Strata Oncology is a precision oncology company that builds clinically validated genomic and RNA‑based biomarkers and diagnostic tests to match patients with appropriate cancer therapies, including predictive scores for immunotherapy and antibody–drug conjugates (ADCs). [4][2]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech and Life‑Sciences Landscape
Quick Take & Future Outlook
Sources cited above include Strata’s corporate site and product pages, company news releases, and industry profiles summarizing its products, biomarkers, lab capabilities, and recognition in diagnostics innovation.[4][3][1][2]
Strata Oncology has raised $128.0M across 3 funding rounds. Most recently, it raised $90.0M Series C in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 29, 2021 | $90M Series C | Wellington Management | Arboretum Ventures, Baird Capital, Cormorant Asset Management, Deerfield Management, Highside Capital Management, Merck, Monashee Investment Management, Renaissance Venture Capital Fund | Announced |
| May 1, 2018 | $26M Series B | — | Merck Global Health Innovation Fund, Arboretum Ventures, Baird Capital, Deerfield Management, Prem Tumkosit, Renaissance Venture Capital Fund | Announced |
| Jun 2, 2016 | $12M Series A | JAN Garfinkle, Nicole J Walker | Elab Ventures | Announced |
Strata Oncology has raised $128.0M in total across 3 funding rounds.
Strata Oncology's investors include Wellington Management, Arboretum Ventures, Baird Capital, Cormorant Asset Management, Deerfield Management, Highside Capital Management, Merck, Monashee Investment Management, Renaissance Venture Capital Fund, Merck Global Health Innovation Fund, Prem Tumkosit, Jan Garfinkle.